Biocracked
Approach 1, macro science, in palette D, bold color field.

An extreme close-up of a single golden fish oil droplet resting on the cut cross-section of a real cancellous bone sample. The porous, honeycomb-like trabecular structure of the bone is pale ivory and finely detailed. The translucent amber droplet sits on its surface without soaking in, catching a sharp highlight. The backdrop is a saturated tomato-red field, smooth and out of focus, with the bone and droplet in crisp focus. The camera is a slightly elevated 30-degree macro angle with a shallow depth of field. Lighting is a hard, clean studio key from the upper left, with a soft red bounce in the shadows and no blue cast. A tiny electric green reflection glints along the droplet's edge. The mood is skeptical and quietly stark: a promising ingredient that makes no mark on the structure beneath it.
Supplements

Riblje ulje za jačanje kostiju? Studija na 25 871 osobe kaže: razmislite ponovo

Dr. Synapse · · 4 min read

If you take fish oil hoping it will keep your skeleton strong, one of the largest randomized trials ever run on the question has some unwelcome news. In a study of 25,871 generally healthy adults, marine omega-3 supplements did not lower the risk of fractures. The one bone-density bump researchers found was tiny and showed up in only one measurement.


If you take fish oil hoping it will keep your skeleton strong, one of the largest randomized trials ever run on the question has some unwelcome news. In a study of 25,871 generally healthy adults, marine omega-3 supplements did not lower the risk of fractures. The one bone-density bump researchers found was tiny and showed up in only one measurement.


The Hype: Why Fish Oil Seemed Like a Bone Booster


The idea was not unreasonable. The authors note that preclinical studies suggest omega-3 fatty acids may benefit skeletal health. That kind of animal and lab evidence is encouraging, but it often fails to carry over to people. The paper also points out that few randomized controlled trials had tested supplemental omega-3 on bone outcomes in humans. This study was designed to fill that gap.


How the Trial Worked


VITAL was a 2 × 2 factorial, randomized, placebo-controlled trial. It tested marine omega-3 fatty acids, vitamin D3, both, or placebo. Its original purpose was to look at cancer and cardiovascular events. The bone analysis was an ancillary study.


Key design details:


  • Dose: 1 gram per day of marine omega-3, with EPA and DHA in a 1.2:1 ratio
  • Participants: 25,871 U.S. men aged 50 or older and women aged 55 or older
  • Exclusions: People with cancer or cardiovascular disease at baseline were not enrolled
  • Selection: Participants were not chosen for low bone density or prior fracture
  • Timeline: The intervention ran from November 2011 through December 2017, with a median follow-up of 5.3 years
  • Average age: 67.1 years

The primary outcomes were adjudicated incident total, nonvertebral, and hip fractures across the whole cohort. In a smaller subcohort of 771 people, researchers also measured two-year changes in bone density and structure. They used DXA for areal bone mineral density (aBMD). They used peripheral quantitative CT for volumetric BMD, cortical thickness, and bone strength indices at the radius and tibia.


The Fracture Results: Basically Nothing


Omega-3 did not reduce fractures of any type that was measured:


  • Total fractures: HR 1.02 (95% CI 0.92–1.13; p = .73)
  • Nonvertebral fractures: HR 1.01 (95% CI 0.91–1.12; p = .80)
  • Hip fractures: HR 0.89 (95% CI 0.61–1.30; p = .55)

A hazard ratio of 1.0 means no difference between groups. The total and nonvertebral figures sit almost exactly there. The hip fracture estimate is lower at 0.89, but its confidence interval runs from 0.61 to 1.30 and the p-value is .55. That is consistent with no effect, and the study does not support claiming a hip benefit.


The Bone Density Results: One Tiny Blip


In the 771-person subcohort, whole-body aBMD changed by +0.03% in the omega-3 group versus −0.41% in the placebo group (p = .006). The authors describe this as a small increase.


Everything else came up empty. There was no effect on aBMD at the spine or hip. There was no effect on volumetric BMD or on bone strength indices at the radius or tibia. A small whole-body change with no matching improvement at the sites that matter most for fractures is hard to read as meaningful protection. This subcohort also tested several measurements, so one isolated positive among many nulls should be treated cautiously.


Was It Safe?


No serious adverse effects were observed. So the finding is not that fish oil harmed bones. It simply did not help them in this population.


What This Means for You


Who the findings apply to: Generally healthy, community-dwelling midlife and older adults, not selected for low bone density or fracture history. The trial cannot say whether omega-3 helps people with osteoporosis, people at very high fracture risk, or those with other conditions. It also tested one dose and formulation, 1 g/day of EPA plus DHA, so other doses are untested here.


Practical takeaways:


  1. Do not rely on fish oil as a bone strategy. In this trial, 1 g/day over a median of 5.3 years did not reduce total, nonvertebral, or hip fractures.
  2. Don't expect a density boost. The only change was a small whole-body difference, with no benefit at the spine, hip, radius, or tibia.
  3. Timing is not a fix. The trial used a daily supplement and found no fracture benefit, so there is no evidence that a particular time of day would change the result.
  4. If you already take it for other reasons, this study gives no sign of bone harm. Omega-3 has been studied for other health purposes, and those questions are outside this paper. Talk to your clinician about whether it suits your overall situation.
  5. If bone health is your concern, ask your doctor about approaches with stronger evidence. What those are falls outside this paper's scope.

Caveats Worth Knowing


The bone density measurements covered only two years in 771 people, so that part of the study is smaller and shorter than the fracture analysis. The participants were generally healthy and not selected for bone risk, which limits what the trial can say about higher-risk groups. The disclosure statement lists one author as having other financial or material support from Pharmavite.


The Bottom Line


The animal and lab rationale for omega-3 and bone was plausible. In humans, a very large, rigorous trial did not deliver. The authors conclude that marine omega-3 supplementation did not reduce incident fracture risk and had no other effects on BMD or bone strength measures compared with placebo, apart from a small whole-body aBMD increase. For bone protection, fish oil does not appear to be the answer.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: D, bold color field.

A single cracked ceramic-white bone-shaped column, like a femur section, stands upright at the center of a saturated mustard-yellow seamless backdrop. A thin, clean hairline fracture runs through its middle. Beside it, a small golden-amber glass dropper bottle sits tipped, with one droplet suspended just above the bone and not touching it, which suggests extra vitamin D that makes no difference. The camera is at a low three-quarter angle with a shallow depth of field. Hard, directional studio light from the upper left casts a crisp, long shadow across the yellow floor. The porous bone texture is visible in fine detail. A tiny electric green (#00e676) droplet reflection glints on the glass. The mood is skeptical, cool-headed and editorial.
longevity

Visokodozirani vitamin D za kosti? Petogodišnje ispitivanje kaže ne

BY DR. SYNAPSE ·

Uzimate dodatni vitamin D da biste ojačali kosti? Petogodišnja randomizovana studija na 2.495 starijih Finaca pokazala je da ni doze od 1.600 ni 3.200 IU dnevno nisu smanjile broj preloma u odnosu na placebo. Čudno, grupa koja je prima 1.600 IU imala je čak i više preloma (HR 1,52), dok viša doza takav efekat nije pokazala – što ukazuje na moguću slučajnost. Učesnici su već na početku imali dovoljno vitamina D, pa rezultati možda ne važe za osobe s deficitom. Evo šta je studija otkrila, koja su njena ograničenja i šta razmotriti pre nego što kupite još jednu bočicu.

**Approach: Conceptual metaphor. Palette: B, Warm.**

A close, slightly high three-quarter view of a single weathered hemp rope stretched horizontally across the frame, shot at a shallow depth of field. On the left the rope is thick and tightly twisted. On the right it has frayed down to a few thin strands, with a short, neat whipping of bright electric green thread binding the rope just where the fraying stops. Golden-hour sunlight enters low from the left and picks out each individual fiber in honey and copper tones. Soft amber shadows fall across a blurred, sun-warmed wooden dock in the background. The mood is quiet and cautiously hopeful, suggesting something worn down slowly but partly held in place. The image is photorealistic and has no text.
longevity

Vitamin D3 očuvao 140 baznih parova telomera u četvorogodišnjem RCT‑u

BY DR. SYNAPSE ·

Velika, randomizovana, placebom kontrolisana studija otkrila je da četiri godine suplementacije vitaminom D3 usporavaju skraćivanje telomera za otprilike 140 baznih parova. Podaci potiču iz VITAL studije starijih američkih odraslih koji su uzimali 2 000 IU dnevno. Efekat je bio skroman i marginalno statistički značajan (p = 0.039), a dužina telomera je samo surrogatni marker, ne dokaz da ćete živeti duže. Omega‑3 masne kiseline, međutim, nisu imale nikakav učinak na telomere u ovoj studiji. Evo šta brojevi pokazuju, koje su granice i kako razumno iskoristiti ovo otkriće.

Approach 4, conceptual metaphor, in palette D, bold color field.

A single translucent golden-amber oil droplet, about the size of a grape, sits on a glossy saturated teal backdrop. Beside it rest several similar, slightly cloudy and dull droplets, which stand for the other omega-3s that did not show the link. The camera is a low three-quarter angle with a macro lens, so the foreground droplet is razor sharp and the others fall softly out of focus. Soft studio light from the upper left gives the amber droplet a bright rim and a warm caustic glow on the teal surface. A tiny electric green reflection curves along the edge of the hero droplet. The mood is clear, focused and quietly confident. There is no text and no bottles.
longevity

Nije Omega‑3, već DHA: povezanost s 18 % manjim rizikom od slabljenja

BY DR. SYNAPSE ·

Šta ako omega‑3 na etiketi vašeg suplementa nije ono što zaista utiče? Analiza podataka iz UK Biobank na 38 577 odraslih koji nisu bili slabi pokazala je da viši nivo DHA u plazmi, a ne ukupni ili ne‑DHA omega‑3, smanjuje rizik od razvoja slabljenja za 18 % tokom otprilike devet godina. Korist je bila najjasnija za nisku fizičku aktivnost i umor, a ne za snagu stiska ili brzinu hoda. Studija je posmatračka, a jedan od autora poseduje akcije kompanije za testiranje krvi, pa ne može dokazati da suplementi sprečavaju slabljenje.

Approach: macro science. Palette: warm (amber and honey).

Extreme macro photograph of a single golden droplet of DHA-rich fish oil suspended at the tip of a glass pipette, shot at eye level with a shallow depth of field. Inside the droplet, a tiny inverted reflection of a window shows through like a lens. Behind it, a softly blurred second droplet rests on a curved glass surface, catching a thin rim of light. Backlit by low golden-hour sunlight from camera left, producing glowing honey and copper tones, warm brown shadows, and delicate caustic patterns on the surface below. The oil shows fine texture, with microscopic bubbles and a slight viscous sheen. A faint electric green reflection glints along the pipette's edge. The mood is quiet, precise and hopeful, with a clean, uncluttered composition and generous empty space on the right. Photorealistic, no text.
supplements

DHA za mozak: 12 meseci usporenog gubitka zapremine hipokampusa kod MCI

BY NOVA CHEN ·

Godinu suplementacije DHA usporila je smanjenje zapremine hipokampusa – memorijskog centra mozga – kod starijih osoba sa blagim kognitivnim poremećajem (MCI). U randomizovanom, dvostruko‑slepom pokusu sa 240 učesnika iz Kine (219 je završilo), DHA grupa je takođe nadmašila placebo po ukupnom IQ‑u, testu Informacije i Digit Span. Doza je bila 2 g dnevno suplementa, što u praksi znači oko 0,9 g čiste DHA. Rezultati mogu objasniti zašto su kliničke studije omega‑3 kod zdravih ljudi donosile mešovite zaključke – koristi se verovatno ispoljavaju samo kod onih koji već pokazuju kognitivni pad. Članak razmatra brojke, moguće mehanizme, praktične savete o doziranju i izvoru, i ograničenja jedne studije.

This page is available in